1. Home
  2. ALLR vs KTTA Comparison

ALLR vs KTTA Comparison

Compare ALLR & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

N/A

Current Price

$0.98

Market Cap

19.3M

Sector

Health Care

ML Signal

N/A

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.44

Market Cap

18.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLR
KTTA
Founded
2004
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.3M
18.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
ALLR
KTTA
Price
$0.98
$0.44
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
107.6K
★ 141.8K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 77.07
EPS
N/A
★ N/A
Revenue
$320,000.00
★ $486,559.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 3130.37
52 Week Low
$0.77
$0.28
52 Week High
$1.84
$2.06

Technical Indicators

Market Signals
Indicator
ALLR
KTTA
Relative Strength Index (RSI) 33.62 35.47
Support Level $0.90 $0.43
Resistance Level $1.00 $0.52
Average True Range (ATR) 0.09 0.03
MACD -0.00 -0.01
Stochastic Oscillator 18.69 9.01

Price Performance

Historical Comparison
ALLR
KTTA

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Share on Social Networks: